Featured News

New Phase 2 Clinical Trial: TEV-CeD2 Study

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

What if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.

On May 20 the Disease Foundation hosted its third annual award reception at Digestive Disease Week in Washington, D.C. From prestigious global research prizes to inaugural student and policy leadership awards, the event spotlighted the extraordinary contributions of individuals dedicated to improving the lives of those affected by celiac disease.

The Celiac Disease Foundation is proud to share that for the second year in a row, access to funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP)Peer Review Medical Research Program.

The Celiac Disease Foundation has joined forces with the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Foundation to introduce two groundbreaking awards specifically designed to advance celiac disease research. These initiatives aim to foster novel research endeavors, emphasizing the importance for medical professionals to delve into the complexities of this lifelong autoimmune condition. 

The Celiac Disease Foundation today announced its Board of Directors re-appointments for 2024. The Board represents a diverse mix of professionals, patients, and caregivers who are deeply committed to advancing the Foundation’s mission of accelerating diagnosis, treatments, and a cure for celiac disease.  

The Celiac Disease Foundation is expanding its operations with the appointment of three senior-level staff. These roles are aligned with the Foundation’s latest strategic plan and ongoing work to accelerate diagnosis, treatments, and a cure for celiac disease – one of the world’s most prevalent genetic autoimmune diseases.

The SynCeD Study is looking for adult volunteers with celiac disease to join a phase 2a clinical trial. Your participation could make a difference. 

The Celiac Disease Foundation, the nation’s leading patient advocacy organization for celiac disease, today is proud to announce its newest Board of Directors appointee, Dan Gibbons, who joins the organization this month.